Longer-term (up to 6 Years) Efficacy and Safety of Ofatumumab in People with Non-highly Active MS Early in the Disease Course

Authors
Category Primary study
ConferenceAnnual Meeting of the American Academy of Neurology, AAN 2025
Year 2025
This article has no abstract
Epistemonikos ID: 099df9cb0f380e6358e01ef495babadebec421cf
First added on: Sep 12, 2025